Global Mpox Therapeutics Market to Reach US$132.7 Million by 2030
The global market for Mpox Therapeutics estimated at US$90.0 Million in the year 2024, is expected to reach US$132.7 Million by 2030, growing at a CAGR of 6.7% over the analysis period 2024-2030. Smallpox Vaccine, one of the segments analyzed in the report, is expected to record a 5.4% CAGR and reach US$75.5 Million by the end of the analysis period. Growth in the Antivirals segment is estimated at 9.0% CAGR over the analysis period.
The U.S. Market is Estimated at US$24.5 Million While China is Forecast to Grow at 10.3% CAGR
The Mpox Therapeutics market in the U.S. is estimated at US$24.5 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$27.2 Million by the year 2030 trailing a CAGR of 10.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.4% and 6.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.4% CAGR.
Global Mpox Therapeutics Market - Key Trends & Drivers Summarized
Why Are Antiviral Treatments Central in Mpox Care?
Antiviral treatments are crucial in managing severe mpox cases and limiting complications. These treatments help reduce viral replication once infection is confirmed. Currently available options include antiviral drugs originally developed for related viruses. Access to effective therapeutics enables clinicians to treat high-risk patients, such as immunocompromised individuals, pregnant persons, and children. Early intervention with antiviral therapy improves patient outcomes and reduces the risk of severe disease progression.
Healthcare providers rely on protocols that guide initiation and dosing of antivirals based on clinical severity. Intravenous or oral regimens are selected according to patient condition and drug availability. Treatment also involves monitoring for side effects and adjusting therapy in response to kidney or liver function. In resource-limited settings, timely access to antiviral stockpiles and clear treatment guidelines remain critical for effective patient management.
What New Treatments Are Emerging or Under Study?
Research into novel therapies has intensified due to rising mpox incidence and growing public health interest. Experimental drugs targeting viral replication mechanisms are in various stages of clinical development. Some candidates offer broader antiviral activity. Others are designed specifically for mpox. Research efforts also include evaluating monoclonal antibodies aimed at neutralizing the virus. These treatments may offer passive immunity and support for severe or refractory cases.
Clinical trials focus on assessing safety, dosing, and efficacy across diverse patient groups. Special attention is given to understanding drug impacts in vulnerable populations such as children, elderly people, and immunosuppressed individuals. Drug developers are also exploring combination therapies that pair antivirals with immune modulators to enhance outcomes. Regulatory agencies have begun granting emergency use authorizations for some treatments, enabling broader access while formal approvals progress.
How Are Access and Distribution Evolving?
Mpox therapeutics are being distributed through public health channels, emergency stockpiles, and international aid programs. Partnerships between government agencies, non-governmental organizations, and manufacturers facilitate medicine allocation in low-resource regions. Programs often include training for clinicians to identify eligible patients, manage treatment regimens, and monitor for adverse events. This coordinated approach helps ensure equitable treatment access in outbreak zones.
Pharmaceutical companies are also scaling production capacities and restructuring supply chains to meet increasing demand. They are exploring flexible manufacturing processes that can quickly adapt volumes as needed. Distribution systems now include temperature-controlled transport, real-time tracking, and regional hubs to reach remote areas efficiently. Such logistics enhancements are vital to avoid stockouts and ensure treatment availability during epidemic peaks.
Growth in the Mpox Therapeutics Market Is Driven by Several Factors…
Growth in the mpox therapeutics market is driven by several factors. Rising global mpox cases have increased demand for effective treatments. Emergency authorizations and approvals of new antiviral agents support market expansion. Investment in clinical trials targeting safety and efficacy in vulnerable populations advances therapeutic options. Scale-up of manufacturing capacity and flexible supply chains improves access in diverse settings. Expansion of international aid programs enables distribution in low-resource regions. Growing focus on combination therapies and monoclonal antibodies broadens treatment portfolios and supports future innovation.
SCOPE OF STUDY:
The report analyzes the Mpox Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Treatment (Smallpox Vaccine, Antivirals, Vaccinia Immune Globulin); End-Use (Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use, Other End-Uses)
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Select Competitors (Total 42 Featured) -
Aegis Sciences Corporation
Bavarian Nordic A/S
Baxter International Inc.
BioNTech SE
Chimerix Inc.
CIDIC Company Limited
Emergent BioSolutions Inc.
Emcure Pharmaceuticals Ltd.
Gilead Sciences Inc.
Hetero Drugs Limited
Mylan N.V. (Viatris)
Moderna Inc.
Olon S.p.A.
Piramal Enterprises Ltd.
Pfizer Inc.
Sanofi S.A.
SIGA Technologies Inc.
SymBio Pharmaceuticals Ltd.
Teva Pharmaceutical Ltd.
Tonix Pharmaceuticals
AI INTEGRATIONS
We're transforming market and competitive intelligence with validated expert content and AI tools.
Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Tariff Impact on Global Supply Chain Patterns
Mpox Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Rising Case Burden in Urban and Non-Endemic Regions Drives Demand for Targeted Mpox Treatments
Emergency Use Authorization Pathways Spur Accelerated Development of Antiviral Therapies
Expansion of Zoonotic Virus Research Throws Spotlight on Broader-Spectrum Antiviral Agents
Government Funding and Global Health Partnerships Propel Clinical Trials for Investigational Drugs
Increased Use of Tecovirimat and Cidofovir Strengthens Short-Term Market for Repurposed Therapies
Vaccine-Linked Immunotherapies Generate Adjacent Market Demand for Prophylactic-Therapeutic Combos
Outbreak Management Strategies Support Parallel Growth in Therapeutics Alongside Diagnostics
Cross-Application of Smallpox Therapeutics in Mpox Management Sustains Off-Label Prescriptions
Focus on Reducing Hospitalization and Complication Rates Enhances Demand for Fast-Acting Treatments
Public Health Policies Supporting Post-Exposure Treatment Create Stable Demand for Rapid-Response Drugs
Expansion of National Stockpiles and Strategic Reserves Drives Procurement of Antiviral Therapeutics
Rising Demand for Oral and Injectable Formulations Supports Diverse Product Delivery Options
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Mpox Therapeutics Market Analysis of Annual Sales in US$ for Years 2014 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Mpox Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
TABLE 3: World Historic Review for Mpox Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 4: World 16-Year Perspective for Mpox Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Smallpox Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
TABLE 6: World Historic Review for Smallpox Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 7: World 16-Year Perspective for Smallpox Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Antivirals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
TABLE 9: World Historic Review for Antivirals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 10: World 16-Year Perspective for Antivirals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Vaccinia Immune Globulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
TABLE 12: World Historic Review for Vaccinia Immune Globulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 13: World 16-Year Perspective for Vaccinia Immune Globulin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
TABLE 15: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 16: World 16-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for Specialty Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
TABLE 18: World Historic Review for Specialty Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 19: World 16-Year Perspective for Specialty Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 20: World Recent Past, Current & Future Analysis for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
TABLE 21: World Historic Review for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 22: World 16-Year Perspective for Ambulatory Surgery Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 23: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
TABLE 24: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 25: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
III. MARKET ANALYSIS
UNITED STATES
Mpox Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
TABLE 26: USA Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 27: USA Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 28: USA 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
TABLE 29: USA Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 30: USA Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 31: USA 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
CANADA
TABLE 32: Canada Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 33: Canada Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 34: Canada 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
TABLE 35: Canada Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 36: Canada Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 37: Canada 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
JAPAN
Mpox Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
TABLE 38: Japan Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 39: Japan Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 40: Japan 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
TABLE 41: Japan Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 42: Japan Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 43: Japan 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
CHINA
Mpox Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
TABLE 44: China Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 45: China Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 46: China 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
TABLE 47: China Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 48: China Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 49: China 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
EUROPE
Mpox Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
TABLE 50: Europe Recent Past, Current & Future Analysis for Mpox Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
TABLE 51: Europe Historic Review for Mpox Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 52: Europe 16-Year Perspective for Mpox Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
TABLE 53: Europe Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 54: Europe Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 55: Europe 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
TABLE 56: Europe Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 57: Europe Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 58: Europe 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
FRANCE
Mpox Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
TABLE 59: France Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 60: France Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 61: France 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
TABLE 62: France Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 63: France Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 64: France 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
GERMANY
Mpox Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
TABLE 65: Germany Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 66: Germany Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 67: Germany 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
TABLE 68: Germany Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 69: Germany Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 70: Germany 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
ITALY
TABLE 71: Italy Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 72: Italy Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 73: Italy 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
TABLE 74: Italy Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 75: Italy Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 76: Italy 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
UNITED KINGDOM
Mpox Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
TABLE 77: UK Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 78: UK Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 79: UK 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
TABLE 80: UK Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 81: UK Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 82: UK 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
SPAIN
TABLE 83: Spain Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 84: Spain Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 85: Spain 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
TABLE 86: Spain Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 87: Spain Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 88: Spain 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
RUSSIA
TABLE 89: Russia Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 90: Russia Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 91: Russia 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
TABLE 92: Russia Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 93: Russia Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 94: Russia 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
REST OF EUROPE
TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 96: Rest of Europe Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 97: Rest of Europe 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 99: Rest of Europe Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 100: Rest of Europe 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
ASIA-PACIFIC
Mpox Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Mpox Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
TABLE 102: Asia-Pacific Historic Review for Mpox Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 103: Asia-Pacific 16-Year Perspective for Mpox Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 105: Asia-Pacific Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 106: Asia-Pacific 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 108: Asia-Pacific Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 109: Asia-Pacific 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
AUSTRALIA
Mpox Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
TABLE 110: Australia Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 111: Australia Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 112: Australia 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
TABLE 113: Australia Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 114: Australia Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 115: Australia 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
INDIA
Mpox Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
TABLE 116: India Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 117: India Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 118: India 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
TABLE 119: India Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 120: India Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 121: India 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
SOUTH KOREA
TABLE 122: South Korea Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 123: South Korea Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 124: South Korea 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
TABLE 125: South Korea Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 126: South Korea Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 127: South Korea 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
REST OF ASIA-PACIFIC
TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 129: Rest of Asia-Pacific Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 132: Rest of Asia-Pacific Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
LATIN AMERICA
Mpox Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
TABLE 134: Latin America Recent Past, Current & Future Analysis for Mpox Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
TABLE 135: Latin America Historic Review for Mpox Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 136: Latin America 16-Year Perspective for Mpox Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
TABLE 137: Latin America Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 138: Latin America Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 139: Latin America 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
TABLE 140: Latin America Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 141: Latin America Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 142: Latin America 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
ARGENTINA
TABLE 143: Argentina Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 144: Argentina Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 145: Argentina 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
TABLE 146: Argentina Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 147: Argentina Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 148: Argentina 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
BRAZIL
TABLE 149: Brazil Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 150: Brazil Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 151: Brazil 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
TABLE 152: Brazil Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 153: Brazil Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 154: Brazil 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
MEXICO
TABLE 155: Mexico Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 156: Mexico Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 157: Mexico 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
TABLE 158: Mexico Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 159: Mexico Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 160: Mexico 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
REST OF LATIN AMERICA
TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 162: Rest of Latin America Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 163: Rest of Latin America 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 165: Rest of Latin America Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 166: Rest of Latin America 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
MIDDLE EAST
Mpox Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
TABLE 167: Middle East Recent Past, Current & Future Analysis for Mpox Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
TABLE 168: Middle East Historic Review for Mpox Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 169: Middle East 16-Year Perspective for Mpox Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
TABLE 170: Middle East Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 171: Middle East Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 172: Middle East 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
TABLE 173: Middle East Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 174: Middle East Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 175: Middle East 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
IRAN
TABLE 176: Iran Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 177: Iran Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 178: Iran 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
TABLE 179: Iran Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 180: Iran Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 181: Iran 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
ISRAEL
TABLE 182: Israel Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 183: Israel Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 184: Israel 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
TABLE 185: Israel Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 186: Israel Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 187: Israel 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
SAUDI ARABIA
TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 189: Saudi Arabia Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 190: Saudi Arabia 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 192: Saudi Arabia Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 193: Saudi Arabia 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
UNITED ARAB EMIRATES
TABLE 194: UAE Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 195: UAE Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 196: UAE 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
TABLE 197: UAE Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 198: UAE Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 199: UAE 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
REST OF MIDDLE EAST
TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 201: Rest of Middle East Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 202: Rest of Middle East 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 204: Rest of Middle East Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 205: Rest of Middle East 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
AFRICA
Mpox Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
TABLE 206: Africa Recent Past, Current & Future Analysis for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 207: Africa Historic Review for Mpox Therapeutics by Treatment - Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 208: Africa 16-Year Perspective for Mpox Therapeutics by Treatment - Percentage Breakdown of Value Sales for Smallpox Vaccine, Antivirals and Vaccinia Immune Globulin for the Years 2014, 2025 & 2030
TABLE 209: Africa Recent Past, Current & Future Analysis for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 210: Africa Historic Review for Mpox Therapeutics by End-Use - Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 211: Africa 16-Year Perspective for Mpox Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030